Downloading...
Download

Medicalstocks

Healthcare Critical LevelTechnical Analysis The 200ema has been tested several times, and has worked very well as a mid-term support level. Risk reward ratio is easy to set-up with a 3:1 ratio approximately. Sector & Industry Analysis It is important to note that the industries inside the sector have different performance, which has been very useful to analyze what the market thinks of the risk of healthcare with the election coming up. The following list is the Healthcare Industries with a 6-month performance % move, as well as a some good ETF to follow/trade: Healthcare Technology --> +56% // have not found appropriate ETF. Biotechnology --> +21% // XBI (smaller biotech), IBB (large-cap biotech), ARKG (genomics) Healthcare Equipment --> +19% // IHI Healthcare Providers --> +5.51% // IHF Pharmaceuticals --> -1.3% // IHE
AMEX:XLV
by dorfmanmaster
$BLFS can rise in the next daysContextual immersion trading strategy idea. BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry. The share prose rose after the company had announced preliminary revenue for the second quarter and used the opportunity to raise $75 million — www.fool.com The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $19,14; stop-loss — $17,88. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:BLFSLong
by KozakHlib
Bullish Industry - Protective Gear, N95 Masks, Robust EarningsAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. On 06/25/20, Alpha Pro announced it will join the Russell 2000 and Russell 3000 Indexes. The company is also currently included in the Russell Microcap Index. On 06/23/20, Business Wire announced Aplha Pro serves a $15 Billion dollar Worldwide industry. On 05/06/20, Alpha Pro announced ROBUST earnings that blew away Wall Street estimates. Q1 EPS $0.39 up from $0.09 YoY. In addition, Alpha Pro had 16% growth in its Building Supply segment. The company has experienced a SURGE in customer demand for its "Proprietary" N-95 Particulate Respirator face mask and other PPE products as a result of the pandemic. As of May 1, 2020, the company has approx. $46.8 million in orders for the N-95 mask alone. Alpha Pro has also experienced a robust demand for its "Face Shield" products with orders totaling $13.3 Million as of May 1, 2020. Alpha Pro ended the 1st qtr of 2020 with working capital of $31.6 million and a current ration of a solid 4:1 - (Bullish Ratio - Strong Cash Position) The company currently has NO OUTSTANDING DEBT and an unused $3.5 million credit line. With the recent uptick in COVID-19 infections, more and more states are requiring masks for all activities especially for frontline employees. The need for Alpha Pro products is not going away anytime soon. Rapid Growth should continue far into 2021 and beyond. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
AMEX:APTLong
by HotCharts
Bullish Charts - COVID-19 Play, N95 Masks, Robust EarningsAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. Today looks like a solid break-out in a down market. Alpha Pro is part of a $15 Billion dollar industry. With N95 masks in high demand, I think there's only one way this stock can go, UP... On 5/6/2020, the company reported earnings of $0.39 up from $0.09. Revenue spiked with 47.5% sales growth. On 5/6/2020, The company announced it was debt free. Not many companies can say they're debt free. 52-Week high is around $41.00 Last earnings report was a blockbuster! The company blew past Wall Street estimates and I think they'll continue blowing past estimates into the future. Indicators are Bullish. Daily Chart looks great. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
AMEX:APTLong
by HotCharts
$DXCM: $375 Price Target ShortFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion basis. That being said, let me get into a few key points. Dexcom very recently faced a 52 week high, had positive quarterly earnings, is on a bullish run, outperformed other stocks in the same sector, continues stable growth and has a strong buy rating. It does have some long potential as well, given it is a 2800+ employee company. However, given its long bullish run, I think there is a small chance it could be tipping off. That being said, for a quick profit target, I suggest a $375 short and a reinvestment in some higher growth (but maybe higher risk) stocks.
NASDAQ:DXCMShort
by gamer456148
Cheech n Chong says Sym TriangleDrawn out a few outcomes on this chart sym triangles can break either way its at the top of a run so it looks bullish to me but it also is coming up on the resistance marker of the previous run in October and has yet to make a higher high from that run.... so TECHNICALLY is bearish. either way heres a few trend lines and support/resistance markers for you all. Green is Bearish target with an extended target to the bottom the trend line... Red is Bullish target of the triangle which breaks the trend of the LOCAL high and could retest the large upper trend line at a later date. Best of luck traders hope this helps some of you :) Comment, Like, and discuss can only get better if you all challenge my thoughts/ideas.
C
by CryptoLeroy
NEMUS Bioscience - Possible Entry for medical pain therapyNMUS About: NEMUS Bioscience, Inc. ( NMUS ) , focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need. Entry better on 4h / 1d vs 1w chart here and another CBD stock missed entry for self note. Watching to see if breakout from current level. Future entry TBD. Watch out for random "cannabinoid" being said in your meetings today with TESLA. @pokethebear I do not advocate THC use and consider the current opioid epidemic to be another on-ramp for alternative break-though medicine. Lipitor to Pfizer, Embrel to AMGEN? 10-1 baggers/3 yr focus. #pharmaindustry. 65% insider owned & no sells on record.
N
by Pokethebear
$CELZ Creates W on Chart as it gets Accumulated Ahead of Updates$CELZ DD As It Stands, this is now one of my Long Term plays that I have added to my portfolio: I like what I see here and am glad to have the shares I have. Targeting BILLIONS IN REVENUE FOLKS AND THE TECHNOLOGY IS REAL AND PROVEN. AMAZING!!! WORTHY OF A MARKET CAP 50-100 MILLION TODAY THATS A PPS .104 - .208! Fellow investors it looks to me like management has been busy getting their ducks in a row. Cleaning up notes and debt. Using restricted shares and the CEO himself adding a huge chunk. We see almost 30% shares held by insiders. Are they preparing for something much larger here. I still believe A 2018 BUY OUT IS IN THE WORKS!!! The "ED" rollout continues and the WORD IS GETTING OUT with Creative Medical Technology Holdings gave the Keynote Speaker at Gathering of Health Care Innovators. The Company's Stem Cell Therapies to be Main Subject at Dr. James Veltmeyer's Congressional Health Care Symposium. Finalized with 8K letting us know where everything stands O/S. TOTAL O/S: 480,035,712 (Nothingness with billions in rev's targeted via multiple diverse procedures! 20-36 Billion "ED" alone 18 Billion "MS" alone.) INSIDER OWNERSHIP: 29.9% (143,489,101 shares) FLOAT: 336,546,611 SHARES (This is nothingness folks) SC 13 d/a CREATIVE MEDICAL HEALTH INC. sHARES 68,511,217 PERCENT OF O/S : 14.3% TIMOTHY WARBINGTON sHARES 74,977,884 PERCENT OF O/S : 15.6% TOTAL PERCENT: 29.9% OF O/S INSIDERS HOLD!!! FORM 4's: CREATIVE MEDICAL HEALTH INC. Purchases: 4-11-2018 9.855,290 shares at a price .0138 totaling $136,003 TIMOTHY WARBINGTON Purchases: 4-12-2018 9,855,290 shares at a price .0138 totaling $136,003 TOTAL PURCHASE DOLLAR VALUE: $272,006 8k - Issued 4-13-2018 RECAP's the over a month of transaction: From March 2, 2018 through April 12, 2018, we issued an aggregate of 144,585,823 shares upon the conversions of outstanding notes and 92,023,304 shares upon the cashless exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933. As a result of these issuances, we have outstanding 480,035,712 shares of common stock as of April 12, 2018. TOTAL O/S: 480,035,712 This number matches the O/S number used to calculate the insider percentages above Creative Medical Technology Holdings to be Keynote Speaker at Gathering of Health Care InnovatorsPress Release | 04/12/2018 Creative Medical Technology Holdings to be Keynote Speaker at Gathering of Health Care Innovators The Company's Stem Cell Therapies to be Main Subject at Dr. James Veltmeyer's Congressional Health Care Symposium www.otcmarkets.com Shareholder Update: Creative Medical Technology Holdings $CELZ: NEW UPDATED 03/26/18 DD PACKAGE~~A clinical-stage biotechnology company focused on Urology and Neurology using stem cell treatments. CLICK HERE TO VISIT THE CREATIVE MEDICAL TECHNOLOGY HOLDING, INC WEBSITE ERECTILE DYSFUNCTION CLINICAL TRIALS Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today that debt to affiliate company Creative Medical Health, Inc. in the amount of $136,003.00 is being converted to restricted common shares of stock in Creative Medical Technology Holdings, Inc. "As we certainly have confidence in the fundamentals of Creative Medical Technology Holdings, Inc., in our stem cell technology and in the experience and ability of our network of doctors, scientists and our executives we have determined that this is a prudent action to eliminate additional debt and to continue to build shareholder value. And as a reminder, May 18-20 we'll be at the American Urological Association (AUA) conference at booth 5870 presenting our CaverstemTM erectile dysfunction technology. Our team is excited and ready to go!"
CLong
by StockGuild